+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The impact of platelet count on mortality in unstable angina/non-ST-segment elevation myocardial infarction



The impact of platelet count on mortality in unstable angina/non-ST-segment elevation myocardial infarction



American Heart Journal 151(6): 1214.E1



Expanding the knowledge of pathogenesis of arteriosclerosis points at a central role of platelets in the development of acute coronary syndromes. Therefore, we sought to determine the impact of platelet count on long-term outcome in unstable angina/non-ST-segment elevation myocardial infarction (UA/NSTEMI) receiving contemporary treatment. This prospective cohort study included 1616 consecutive patients with UA/NSTEMI. All patients underwent coronary angiography and, if appropriate, subsequent catheter-based revascularization within 24 hours of admission. Patients were divided in quintiles according to platelet count. The primary end point was all-cause mortality during long-term follow-up of up to 60 months. During follow-up (median 17 months, interquartile range 6-31 months), 89 deaths and 74 nonfatal myocardial infarctions occurred. Patients with higher platelet counts were younger, more often female, and had lower height and weight as compared with patients with lower platelet counts. Mortality was significantly lower among patients in the second quintile of platelet count (181-210 x 10(9)/L) as compared with the other quintiles (hazard ratio 0.39, 95% CI 0.19 to 0.81, P = .011). Kaplan-Meier survival analysis showed cumulative 4-year mortality rates of 12.5%, 3.8%, 10.4%, 9.8%, and 11.4% for patients in the first, second, third, fourth, and fifth quintiles. This association persisted after multivariate adjustment. No association of platelet count and nonfatal myocardial infarctions was observed. We found a nonlinear association between platelet count and long-term mortality. The lowest mortality was observed in patients with a platelet count between 181 and 210 x 10(9)/L.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 012659283

Download citation: RISBibTeXText

PMID: 16781221

DOI: 10.1016/j.ahj.2006.03.011


Related references

Coronary Flow Assessment in Unstable Angina/non ST-segment Elevation Myocardial Infarction Patients via Thrombolysis in Myocardial Infarction Frame Count in Angiography. Research in Cardiovascular Medicine 2(2): 95-98, 2013

Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE): updated standing orders for ST-segment elevation myocardial infarction and unstable angina/non-ST-segment elevation myocardial infarction. Critical Pathways in Cardiology 9(2): 55-81, 2010

Comparison of outcomes of patients ≥ 80 years of age having percutaneous coronary intervention according to presentation (stable vs unstable angina pectoris/non-ST-segment elevation myocardial infarction vs ST-segment elevation myocardial infarction). American Journal of Cardiology 108(10): 1395-1400, 2011

Oral antiplatelet therapy in unstable angina/non-ST-segment elevation myocardial infarction, ST-segment elevation myocardial infarction, and percutaneous coronary intervention: is it time for a guideline update?. American Journal of Cardiology 104(5 Suppl): 4c, 2009

Update: Use of platelet glycoprotein IIb/IIIa inhibitors in patients with unstable angina and non-ST-segment elevation myocardial infarction. Annals of Emergency Medicine 56(5): E1, 2010

Recurrent ischaemia in patients with unstable angina or myocardial infarction without ST-segment elevation treated with eptifibatide predicts mortality and infarction A report from the PURSUIT study. European Heart Journal 19(ABST Suppl. ): 598, 1998

Incorporating platelet glycoprotein IIb/IIIa inhibition in critical pathways: unstable angina/non-ST-segment elevation myocardial infarction. Clinical Cardiology 22(8 Suppl): Iv30, 1999

Platelet glycoprotein IIb/IIIa blockers for percutaneous coronary revascularization, and unstable angina and non-ST-segment elevation myocardial infarction. Cochrane Database of Systematic Reviews 2001(4): Cd002130, 2001

Circulating high-mobility group box 1 and cardiovascular mortality in unstable angina and non-ST-segment elevation myocardial infarction. Atherosclerosis 221(2): 490-495, 2012

Evidence-based emergency medicine. Use of platelet glycoprotein IIb/IIIa inhibitors in patients with unstable angina and non-ST-segment elevation myocardial infarction. Annals of Emergency Medicine 40(5): 518-520, 2002

Homocysteine predicts adverse clinical outcomes in unstable angina and non-ST elevation myocardial infarction: implications from the folate intervention in non-ST elevation myocardial infarction and unstable angina study. Coronary Artery Disease 19(3): 153-161, 2008

Impact of Clinical Presentation (Stable Angina Pectoris vs Unstable Angina Pectoris or Non-ST-Elevation Myocardial Infarction vs ST-Elevation Myocardial Infarction) on Long-Term Outcomes in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. American Journal of Cardiology 116(6): 845-852, 2015

Health-related quality of life after interventional or conservative strategy in patients with unstable angina or non-ST-segment elevation myocardial infarction: one-year results of the third Randomized Intervention Trial of unstable Angina (RITA-3). Journal of the American College of Cardiology 45(2): 221-228, 2005

Renal function and long term mortality after unstable angina/non-ST segment elevation myocardial infarction treated very early and predominantly with percutaneous coronary intervention. Heart 90(8): 902-907, 2004

Impact of diabetes mellitus on long-term outcome after unstable angina and non-ST-segment elevation myocardial infarction treated with a very early invasive strategy. Diabetologia 47(7): 1188-1195, 2004